Latest Lead News

JPMorgan Asset Management has revised the estimated cash distributions for its four Equity Premium Income Complex ETFs for August 2026, with payments scheduled mid-month.

ActivEX Limited has identified multiple high-grade gold, silver, and base metal targets from surface rock sampling at its Georgetown Project in Queensland, revealing promising prospects for further exploration.

Ballymore Resources has confirmed further high-grade silver-lead-zinc-indium mineralisation at its Torpy's discovery in North Queensland, extending mineralisation closer to surface and supporting an emerging high-grade shoot model.

Brightstar Resources reports steady July progress at its Goldfields Project, maintaining schedule and budget for first gold production in mid-2027 with key infrastructure milestones reached.

TG Metals has raised A$2.5 million through a placement backed by institutional investors and insiders to fund resource expansion, scoping studies, and direct shipping ore opportunities at its Western Australian gold and lithium assets.

Neurotech International has secured $4.5 million through a share placement to fund its pivotal Phase III clinical trial of NTI164 for Autism Spectrum Disorder, aiming to reach topline data readout.

Lincoln Minerals has confirmed ongoing mineralisation at its Minbrie Copper Project’s Eagle Ridge prospect through air core drilling, setting the stage for a targeted diamond drilling campaign later this year.

OMG Group smashed its July sales record with net sales soaring to approximately $738,000, a 120% jump on last year, reversing typical seasonal declines and boosted by a refreshed Blue Dinosaur brand.

Embark Early Education has secured a $4 million placement from a US institutional investor to fuel potential asset acquisitions, issuing 10 million new shares at $0.40 each under its 10% placement capacity.

Amplia Therapeutics has teamed up with Eli Lilly to test its FAK inhibitor narmafotinib alongside Lilly’s KRAS G12C inhibitor olomorasib in advanced non-small cell lung cancer, marking a strategic expansion beyond pancreatic and ovarian cancers.

Rua Bioscience has gained regulatory approval in New Zealand for five new medicinal cannabis products, setting the stage for domestic sales and advancing its strategy to integrate local cannabis genetics.

EROAD has appointed David Leach as CEO, effective October 2026, aiming to leverage his SaaS scaling expertise to accelerate growth and develop an AI-native platform.